Reach Us +1-217-403-9671
Strategies For Development And Validation Of Immunogenicity Assays To Support Preclinical And Clinical Biosimilar Programs | 8167
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Strategies for development and validation of immunogenicity assays to support preclinical and clinical biosimilar programs

International Conference and Exhibition on Biowaivers & Biosimilars

Kelly S. Colletti

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.S1.002

An area of intense focus in the preclinical and clinical testing of biosimilars is the measurement of anti-drug antibodies and comparison of relative immunogenicity rates of the biosimilar and the innovator products. Although the draft FDA guidance for biosimilars was issued earlier this year, there is a clear lack of detail in the description of how these assays should be developed, validated and implemented within a biosimilar program. This presentation will focus on the strategies that can be employed to develop and validate immunogenicity assays to support preclinical and clinical biosimilar programs. The debate currently underway amongst the scientific community to determine if one or two assays are necessary to compare the immunogenicity rates between the biosimilar and innovator products in these programs will be analyzed. This presentation will also investigate some of the pros and cons to the various strategies that may be employed to support a preclinical and clinical biosimilar program. It is imperative that a scientifically sound approach be used when embarking on the development and validation of immunogenicity assays to support a biosimilar program
Kelly Colletti obtained her PhD in Cellular and Molecular Biology at the University of Nevada, Reno in 2005. She is a trained herpes virologist that studied the molecular mechanisms of Cytomegalovirus and Karposi?s Sarcoma Associated Herpes Virus DNA replication. While pursuing her doctoral degree, she learned a diverse set of skills including protein expression and purification, antibody generation, enzymatic assay development, cell culture, molecular biology and protein chemistry. She also obtained an MBA during this time and has a keen business sense. Her postdoctoral fellowship was also in virology developing a reverse genetics model for the Sin Nobre Hantavirus. Kelly joined Charles River in early 2009 and has since become the lead scientist for large molecule bioanalysis and immunogenicity testing at Charles River, Preclinical Services, NV. She is also cross trained in immunotoxicology and has experience running studies in Non-Human Primates with immunophenotyping, TDAR, NK cell activity, and cytokine analysis endpoints. Since joining CRL, Kelly has participated in over 10 biosimilar programs validating bioanalytical and immunogenicity assays to support preclinical and clinical studies